StockpollyBeta
Get App
Delisting riskPopularity #4,349
JUNS · NASDAQ · Biotechnology

Jupiter Neurosciences (JUNS)

Develops CNS drug candidates and sells Nugevia longevity supplements.

$2.94
vs last close−0.04 (−1.28%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
111101222323
Research & development000000011−201
100001121322
General & administrative100001121322
Other expenses000000000200
Operating income−1−1−1−10−1−2−2−2−3−2−3
000100000000
Interest income000000000000
Interest expense000000000000
Other non-operating income000−100000000
Income before tax−20−10−1−2−2−2−2−3−2−2
Net income from continuing operations−20−10−1−2−2−2−2−3−2−2
Net income−20−10−1−2−2−2−2−3−2−2
EPS, basic−$0.07−$1.05−$1.45$0.71−$1.42−$3.84−$3.47−$5.09−$5.25−$5.61−$4.39−$4.08
EPS, diluted−$0.07−$1.05−$1.45$0.71−$1.42−$3.84−$3.47−$5.09−$5.25−$5.61−$4.39−$4.08
Weighted average shares, basic2600000000001
Weighted average shares, diluted2600000000001
EBITDA−20−100−1−2−2−2−3−2−3
Depreciation & amortization000000000000
EBIT−20−100−1−2−2−2−3−2−3